Yungjin Pharm. Co., Ltd.

KSE 003520.KS

Yungjin Pharm. Co., Ltd. Gross Profit Margin for the year ending December 31, 2023: 30.70%

Yungjin Pharm. Co., Ltd. Gross Profit Margin is 30.70% for the year ending December 31, 2023, a 3.57% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

Yungjin Pharm. Co., Ltd. Gross Profit Margin for the year ending December 31, 2022 was 29.64%, a 0.32% change year over year.
Yungjin Pharm. Co., Ltd. Gross Profit Margin for the year ending December 31, 2021 was 29.55%, a -16.15% change year over year.
Yungjin Pharm. Co., Ltd. Gross Profit Margin for the year ending December 31, 2020 was 35.24%, a -2.59% change year over year.
Yungjin Pharm. Co., Ltd. Gross Profit Margin for the year ending December 31, 2019 was 36.18%, a 9.76% change year over year.

Key data

Date	Gross Profit Margin	Operating Income Margin	EBT Margin	Net Income Margin

KSE: 003520.KS

Yungjin Pharm. Co., Ltd.

CEO	Mr. Chae-Joon Lee
IPO Date	Jan. 8, 2001
Location	South Korea
Headquarters	13, Olympic-ro 35da-gil
Employees	574
Sector	Health Care
Industries Pharmaceuticals Drugstores & Retail Pharmacies

Description

Yungjin Pharm. Co., Ltd. operates as a pharmaceutical company in South Korea. It provides cephalosporin antibiotic, antipsychotic, cardiovascular, and nutrition products. The company was founded in 1952 and is headquartered in Seoul, South Korea. Yungjin Pharm. Co., Ltd. is a subsidiary of KT&G Corporation.

Key trends

Past 5 years